SCHEDULE: Coastlands Capital Discloses Pyxis Oncology Stake
Schedule 13G Filing
Coastlands Capital and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of 5.42% of Pyxis Oncology's common stock as of October 1, 2026.
Summary
- Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry have entered into a joint filing agreement.
- They are jointly reporting beneficial ownership of 6,448,907 shares of Pyxis Oncology, Inc. common stock.
- This represents 5.42% of the class of securities outstanding as of October 1, 2026.
- The filing is made under Schedule 13G, indicating passive investment intent.
- The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest and do not claim to be a group.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a change in reporting status and a significant but not controlling stake, without immediate news of operational changes or financial performance.
Positives
- The joint filing agreement establishes a clear reporting structure for the entities involved.
- The reporting of a 5.42% stake indicates a significant investment in Pyxis Oncology.
- The Schedule 13G filing suggests a passive investment approach, which can be viewed positively by the market as it implies no intent to control or disrupt management.
Negatives
- The filing does not provide any new financial performance data or strategic updates for Pyxis Oncology.
- The exact pecuniary interest of each reporting person is not detailed, only the aggregate shared voting and dispositive power.
Risks
- The filing does not explicitly mention any risks associated with the investment or Pyxis Oncology's business.
- Potential future changes in investment strategy by Coastlands Capital could impact Pyxis Oncology's stock.
Future Outlook
The filing itself does not contain forward-looking statements or guidance regarding Pyxis Oncology's future performance. It solely pertains to the reporting of beneficial ownership.
Management Comments
- Each reporting person disclaims beneficial ownership of Common Stock except to the extent of that person's pecuniary interest therein.
- The Partnership disclaims that it is a beneficial owner as defined in Rule 13d-3 under the Act of any Common Stock covered by this Schedule 13G.
Industry Context
StockSavvy.ai notes that the filing of a Schedule 13G by investment entities is common in the biotechnology sector, often indicating significant stakes taken by institutional investors. This filing by Coastlands Capital suggests a notable position in Pyxis Oncology, a company operating in this dynamic industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Joint Filing Agreement | Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, and Matthew D. Perry have agreed to file jointly any and all statements on Schedule 13D or 13G. | October 5, 2026 | Establishes a coordinated reporting mechanism for these entities regarding their securities holdings. |
Stakeholder Impact
- Shareholders: The filing provides transparency regarding a significant ownership stake, which may influence market perception and trading activity.
- Management of Pyxis Oncology: The passive nature of the Schedule 13G filing suggests no immediate intent to influence control, which may be viewed as stable by management.
Next Steps
- Coastlands Capital and affiliated entities will continue to file joint statements on Schedule 13D or 13G as required.
- Future amendments to the Schedule 13G will be filed if there are changes in beneficial ownership or other reportable events.
Key Dates
| Date | Description |
|---|---|
| 10/01/2026 | Date of event requiring filing (acquisition of shares) and date as of which shares outstanding were calculated. |
| 10/05/2026 | Date of the Agreement Regarding Joint Filing and signature date for the Schedule 13G. |
Keywords
Pyxis Oncology, Coastlands Capital, Schedule 13G, Beneficial Ownership, Joint Filing, Investment, Common Stock, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.